Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A retrospective nomogram development and validation study in a single centre with good discrimination metrics (AUROC 0.901) and internal validation, but based on a surrogate endpoint (elevated troponin) rather than hard clinical outcomes, limiting generalizability.
A narrative review synthesizing current evidence on circulating biomarkers in cardio-oncology, recommending multimodal assessment strategies but acknowledging gaps in validation and standardization rather than reporting new primary data.
A clinical review synthesizing mechanistic rationale, randomized trial evidence, and imaging data to propose a selective, physiology-guided framework for side branch ballooning in bifurcation PCI—positioned to inform practice rather than report a new trial result.
Hospital-based cross-sectional study with large sample and multivariate analysis showing age-specific associations between metabolic phenotypes and angiographically confirmed CAD, but lacks a prospective design and causal inference; findings in young adults are novel but require validation.
A small single-centre imaging study with surrogate endpoints (calcium score and FDG uptake) showing a signal of chemoradiotherapy-associated aortic atherosclerosis progression, but lacking hard clinical outcomes and requiring confirmation.
A pragmatic cluster-randomized trial in primary care showing CACS reduces unnecessary cardiology referrals and improves preventive enrolment, but fails on the primary outcome (practice-level CVRM registration) and detects similar OCAD rates; limited by non-blinded design, imbalanced per-protocol sample, and lack of hard clinical endpoints.
A single case report with no control group, describing a temporal association between cancer therapy and acute MI; raises a mechanistic hypothesis but provides no quantified risk or causal evidence.
This is a narrative review that raises questions about cardiac troponin's role in cardio-oncology rather than reporting original research findings or definitive evidence.